Ophthalmology · Ocular Pharmacology and Therapeutics (Anti-VEGF, Anti-glaucoma Classes, Steroids)

Which intravitreal anti-VEGF agent binds VEGF-A, VEGF-B, AND placental growth factor (PlGF), giving it the broadest VEGF-family binding profile among currently approved agents?

  • A Ranibizumab
  • B Bevacizumab
  • C Aflibercept
  • D Brolucizumab
Correct answer: C. Aflibercept

Explanation

Aflibercept (VEGF Trap) is a fusion protein combining the binding domains of VEGFR-1 and VEGFR-2 fused to the Fc of IgG1. It binds VEGF-A (all isoforms), VEGF-B, and PlGF — the broadest VEGF-family profile. Ranibizumab and bevacizumab bind only VEGF-A. Brolucizumab is a single-chain antibody fragment (scFv) that binds VEGF-A only (with very high affinity).

Reference: Khurana Comprehensive Ophthalmology, 7th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.

Sponsored

Want to test yourself?

Create a free account for timed mock tests, mistake tracking, and FSRS spaced-repetition revision across 23,000+ MCQs.

Start free → Log in

More Ocular Pharmacology and Therapeutics (Anti-VEGF, Anti-glaucoma Classes, Steroids) MCQs

See all Ocular Pharmacology and Therapeutics (Anti-VEGF, Anti-glaucoma Classes, Steroids) MCQs →